Drugs › Interleukin-12 antagonist
Brand name · Ustekinumab
Stelara: adverse event reports filed with FDA
86,538 reports list it as a suspect or interacting product, 2009–2026. Class: Interleukin-12 antagonist.
- 86,538
- reports as suspect product
- 0.4% of all reports · about 5,168 a year
- 3,243
- reports, 12 months to June 2026
- 6,309 in the 12 months before
- 54.7%
- marked serious by the reporter
- 58.5% across the class
- 5.2%
- record death among outcomes, as reported
- 4,513 reports · not verified by FDA
Between October 2009 and June 2026, 86,538 adverse event reports received by FDA list the brand name Stelara (ustekinumab) as a suspect or interacting product. Reports that mention it only as a concomitant medication (6,525) are left out of every figure here.
In the 12 months to June 2026, 3,243 reports listed it, down 49% from 6,309 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 5,168 reports a year and 0.4% of the 20,646,523 reports in the database, and 90.9% of the reports for the interleukin-12 antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are drug ineffective (13.6%), off label use (12.4%) and product dose omission issue (11.4%). A report can list several reactions, so shares add to more than 100%; 2,729 different terms appear across these reports. Drug ineffective is recorded in 13.6% of these reports, a smaller share than in the median interleukin-12 antagonist drug (19.5%).
54.7% of the reports are marked serious by the reporter (58.5% across the class); 5.2% record death among the outcomes and 19.5% record hospitalisation, as reported. 36.3% of the reports came from consumers, and the largest patient age group is 18 to 44 (21.8%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Stelara reports recording the termmedian drug in interleukin-12 antagonist
- Drug ineffectivethe medicine did not work as expected13.6%11,773
- Off label useused for a purpose or in a way not on the label12.4%10,723
- Product dose omission issuea dose was missed11.4%9,894
- Fatiguetiredness6.1%5,311
- Psoriasispsoriasis, a skin condition5.9%5,064
- Product use issuea problem in how the product was used5.6%4,838
- Painpain, site not specified5.4%4,657
- Rashskin rash5.3%4,550
- Arthralgiajoint pain5.2%4,463
- Crohn's disease5%4,338
- Infusion related reactiona reaction during or soon after an infusion5%4,311
- Condition aggravatedthe condition being treated got worse4.8%4,159
- Headachehead pain4.7%4,048
- Hypersensitivityan allergic-type reaction4.4%3,838
- Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease4.4%3,817
- Lower respiratory tract infectiona chest infection4.3%3,744
- Alopeciahair loss4.3%3,738
- Synovitis4.3%3,687
- Joint swellinga swollen joint4.2%3,676
- Hepatic enzyme increasedraised liver enzymes4.2%3,646
- Abdominal discomfortstomach discomfort4%3,455
- Diarrhoealoose or frequent stools4%3,442
- Systemic lupus erythematosuslupus, an autoimmune disease3.9%3,401
- Drug intolerancethe medicine was not tolerated3.9%3,383
- Pneumonialung infection3.9%3,352
- Swellingswelling3.8%3,289
- Wound3.8%3,277
- Psoriatic arthropathy3.8%3,273
- Arthropathy3.8%3,251
- Hand deformity3.8%3,249
Top 30 of 2,729 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the interleukin-12 antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 95,243 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 57% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Psoriasis | 21,652 | 25% |
| Crohn's disease | 19,603 | 22.7% |
| Psoriatic arthropathy | 4,676 | 5.4% |
| Colitis ulcerative | 3,306 | 3.8% |
| Rheumatoid arthritis | 1,981 | 2.3% |
| Inflammatory bowel disease | 349 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 86,538 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Stelara reports |
|---|---|---|
| Methotrexate | 8,851 | 10.2% |
| Humira | 8,564 | 9.9% |
| Enbrel | 7,007 | 8.1% |
| Prednisone | 6,940 | 8% |
| Remicade | 6,926 | 8% |
| Folic acid | 6,333 | 7.3% |
| Sulfasalazine | 6,277 | 7.3% |
| Simponi | 6,236 | 7.2% |
| Cimzia | 5,880 | 6.8% |
| Xeljanz | 5,706 | 6.6% |
Other products listed in reports where Stelara is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Stelara | Interleukin-12 antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 86,538 | 95,243 | 20,646,523 |
| Share of that pool | — | 90.9% | 0.4% |
| Reports, latest 12 months | 3,243 | — | 1,332,454 |
| Marked serious | 54.7% | 58.5% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 52 | 67 | 91 |
| Hospitalisation recorded, per 1,000 reports | 195 | 218 | 213 |
| Consumer-filed share | 36.3% | 34% | 45.8% |
| Top term, share of reports | Drug ineffective 13.6% | median 19.5% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the interleukin-12 antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Ustekinumab | generic | 8,705 | 2,396 | 96.2% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Stelara reports
How many adverse event reports has FDA received for Stelara?
86,538 reports list Stelara as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 3,243 of them arrived in the latest 12 months. Another 6,525 list it only as a concomitant medication.
What reactions are recorded in Stelara reports?
drug ineffective (13.6%), off label use (12.4%), product dose omission issue (11.4%), fatigue (6.1%) and psoriasis (5.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Stelara was responsible.
How serious are the reports?
54.7% are marked serious by the reporter. Among the outcomes recorded, 5.2% of reports include death and 19.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (36.3%), other health professional (35.8%) and physician (17.4%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Stelara rising?
3,243 reports in the 12 months to June 2026, down 49% from 6,309 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Stelara was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Stelara?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Stelara as a suspect or interacting product; reports listing it only as a concomitant medication (6,525) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.